Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical
Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
SPRING, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) - Io Therapeutics, Inc., presented results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration with its clinical stage experimental therapeutic RXR agonist compound IRX4204. The presentation titled “The highly potent and selective third generation RXR nuclear receptor agonist compound IRX4204 has potential for prevention and treatment of normal aging-related neurodegeneration” was presented at the FASEB Research Conference on Cellular and Molecular Mechanisms of Brain Aging, being held in Niagara Falls, NY, USA. The presentation was authored by Vidyasagar Vuligonda, Ph.D., Chief Science Officer, and Martin E. Sanders, M.D., Chief Executive Officer.
Normal aging-related neurodegeneration is causally related to chronic low-grade inflammation in the brain, so called neuro-inflammaging. Neuro-inflammaging results in chronic loss of myelinated nerve fibers which conduct neuroelectric signals for communication between neurons. Over time, neuro-inflammaging also results in death of neurons. These natural processes start in the brains of normal healthy humans around the third decade of life, and progress with gradual decline of cognitive, memory, special senses, and physical functions through the remainder of life.
The studies showed that IRX4204 inhibits brain inflammation by decreasing production of the pro-inflammatory cytokine IL-6 by microglial cells. It also promotes growth of immunosuppressive regulatory Treg cells and inhibits Th17 cells from producing the pro-inflammatory cytokine IL-17. Thereby IRX4204 has pharmacologic mechanisms of action addressing two types of neuroinflammation observed in normal aging-related neurodegeneration. IRX4204 also promotes development of myelin-producing cells, which protect and repair damaged myelinated nerve fibers. Further, IRX4204 has direct effects on survival of neurons, and neurorestorative effects on neurons, by increasing their growth of neurites. These effects were observed with IRX4204 alone, and synergistically in combination with insulin, demonstrating IRX4204 has insulin sensitizing activity on neurons. Neuronal insulin insensitivity is a known contributing factor to brain aging. Cumulatively, these studies demonstrated that IRX4204 has benefit on multiple processes of normal brain aging, i.e., neuroinflammation, loss of myelinated nerve fibers, neuronal insulin insensitivity, loss of neuronal interconnections, and decreased neuron survival.
Dr. Vuligonda stated, “These findings support the potential of IRX4204 for prevention and treatment of normal aging-related neurodegeneration. Because we observed restoration of lost myelinated nerve fibers, and formation of new neurites, both of which could restore functional inter-neuronal communications, we believe that IRX4204 has potential for reversing to some degree the cognitive decline and other disabling manifestations of normal brain aging.”
Dr. Sanders stated “Io Therapeutics has previously observed promising potential benefit of IRX4204 in a pilot open-label clinical trial of IRX4204 in patients with Parkinson's disease. The company is planning a placebo-controlled double-blind phase II clinical trial of IRX4204 in Parkinson's disease, to be initiated in Q1 of 2025. We look forward to also conducting exploratory clinical trials of IRX4204 in individuals experiencing normal-aging related neurodegeneration.”
About Io Therapeutics: Io Therapeutics, Inc. is a privately held company headquartered in Spring, Texas. More information on Io Therapeutics and its product development programs is available on the company's web site: www.io-therapeutics.com
Forward Looking Statements: This new release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
Contact:
info@io-therapeutics.com
- 深度解读|2023中国卫生健康服务体系创新案例集
- 赫曼为东方电气集团下属东方电机公司提供水轮机大型球阀水压智能
- 农发行晋中市分行:围绕“三个聚焦” 助推高质量发展
- 哈曼和CARIAD宣布将为大众旗下车辆打造新型应用程序生态系统
- 2023中华夫人国风大典泰国全球总决赛暨2024中华夫人全球颁奖盛典圆满落幕 王慧 陈美贞 蔡淑萍夺得不同组别的全球冠军
- Solavita起明电站三大件配合无间,见证一座电站原装智造的诞生
- 村田将2016尺寸、具有行业超高水平的低直流电阻、支持大电流且高耐压的车载用金属功率电感器实现商品化
- 全球买家齐聚高交会 高新企业蓄势腾飞
- 临商银行罗庄支行加强突发事件紧急信息报送工作培训和学习
- 汉尔姆助力“杭州市临平区第一人民医院”改扩建,构建暖心舒适高品质疗愈空间
- 【喜迎七一建党节特别报道】 國宝级國医大师——周培富
- 村播学院携手崇高健康大舞台 开启直播栏目新形式
- 2024福州高博会 | 华栖云AI+多维数字智慧教育模式精彩亮相
- 著名国宝级,新时代国医大师,中国工程院医学院士---计怀安
- 中国梦引领,圆梦中华项目正式启动
- 面对“无法治愈”青光眼,医生为什么让患者坚持治疗呢?——福州爱尔
- TMC and SGS Produce World-First Cobalt Sulfate from Deep-Seafloor Polymetallic Nodules
- “我爽iFRESH”乌梅芦荟饮品,引领新一代健康饮品潮流
- 木丹颗粒:帮糖尿病患者拔掉悬在头顶的危险之剑
- 2024杭州印刷包装工业展5月9日启幕,省/市/县协会联动,共推浙江印刷高质量发展
- Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Curr
- 欧孚光缆厂家:通信光电复合缆的优势及应用4
- 东莞市锦航五金制品有限公司,为您制定专属五金加工方案!
- 2023河北省优秀基层文艺院团文化惠民演出活动圆满结束
- EP4S100G2F40I3G: Revolutionizing Integrated Circuit Technology | ChipsX
- 又一盛举,沃飞取得关键技术突破后,助力成都低空载人交通航线运行实践!
- 杭州天目山医院耳鼻喉特色专科:打造华东规范化耳鼻喉诊疗中心
- 仓储物流新概念,南京金棠仓储设备制造有限公司领航行业创
- 张伯礼莅临仲景宛西制药展位指导,称赞仲景六味地黄丸最好
- 东方之花绽放全球丨花皙蔻携牡丹系列亮相东盟 迈出品牌国际航迹第一步
推荐
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯